Articles

Updated analysis of the first-in-human phase 1/2 trial showed that BCMA x CD3 bispecific monoclonal antibody REGN5458 monotherapy resulted in early, deep, and durable responses with an acceptable safety and tolerability profile in heavily pretreated patients with RRMM. Read More ›

Updated results of the KarMMa trial showed that ide-cel CAR T-cell therapy resulted in durable and deep responses in heavily pretreated, triple-class–exposed patients with RRMM, supporting an overall favorable clinical benefit–risk profile. Read More ›

Data from the ongoing phase 1/2 MajesTEC-1 study suggested that treatment with the BCMA x CD3 bispecific antibody teclistamab induced deep and durable responses in heavily pretreated patients with RRMM, with a manageable safety profile. Read More ›

The 18-month longer follow-up results of the ANDROMEDA study demonstrated sustained clinical benefits of D-VCd versus VCd in terms of hematologic and organ responses in patients with newly diagnosed light chain amyloidosis, with no additional safety signals. Read More ›

Corneal event management guidelines were developed with the goal of assisting practicing hematologists/oncologists in assessing and managing belantamab mafodotin–associated ocular events so that patients may continue to maximize clinical benefit with belantamab mafodotin therapy. Read More ›

Results of the phase 2 HOVON 143 study indicate that ixazomib, daratumumab, and dexamethasone is an effective and feasible regimen in intermediate-fit patients with non–transplant-eligible NDMM. Read More ›

Results of a phase 2 IFM study demonstrated that quadruplet combination regimen of D-IRD as induction and consolidation therapy after ASCT followed by lenalidomide maintenance therapy was safe and resulted in increased depth of responses over time in standard-risk patients with NDMM. Read More ›

Results of part B of a phase 1b trial showed that the addition of isatuximab (using the short-duration, fixed-volume infusion method) to standard-of-care VRd was feasible, safe, and effective in patients with NDMM ineligible or with no immediate intent for ASCT. Read More ›

Preliminary results of the phase 1 MagnetisMM-1 study indicated that the BCMA-targeted CD3-engaging bispecific molecule elranatamab had a manageable safety profile and induced deep and durable clinical responses as a single agent in heavily treated patients with RRMM. Read More ›

Final analysis results of the LYRA study demonstrated that daratumumab in combination with CyBorD induction therapy and as maintenance yielded durable and deep responses in patients with newly diagnosed or recurrent MM irrespective of ASCT status, with no new safety signals. Read More ›